Table of contents
February 2008 Vol 8 No 2
From the editors
p73 | doi:10.1038/nrc2327
Research Highlights
Cell signalling: Balancing act | PDF (219 KB)
p75 | doi:10.1038/nrc2320
Signalling: Structural survey | PDF (160 KB)
p76 | doi:10.1038/nrc2315
Drug resistance: Destabilizing influence | PDF (330 KB)
p76 | doi:10.1038/nrc2316
In the news
Within spitting distance | PDF (76 KB)
p76 | doi:10.1038/nrc2323
Trial Watch
Language function in patients with glioma | PDF (197 KB)
p77 | doi:10.1038/nrc2324
Cell death: ..and a nice Chianti | PDF (250 KB)
p78 | doi:10.1038/nrc2313
Tumorigenesis: First or last? | PDF (222 KB)
p78 | doi:10.1038/nrc2314
In brief
Mouse models | Mouse models | Tumour suppressors | Diet | PDF (95 KB)
p79 | doi:10.1038/nrc2322
Genetics: In the driving seat | PDF (272 KB)
p80 | doi:10.1038/nrc2318
Signalling: The GEP100 pathway to invasion | PDF (279 KB)
p80 | doi:10.1038/nrc2319
Nanotechnology: Drawing tumour cells from blood | PDF (253 KB)
p81 | doi:10.1038/nrc2317
Reviews
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation
Markus Welcker & Bruce E. Clurman
p83 | doi:10.1038/nrc2290
The tumour suppressor FBW7 is the substrate recognition component of the SCF-type ubiquitin ligase that degrades several proto-oncogenes, including MYC and cyclin E. How do the numerous cancer-associated mutations in FBW7 and its substrates contribute to tumorigenesis?
New approaches for imaging tumour responses to treatment
Kevin Brindle
p94 | doi:10.1038/nrc2289
Tumour responses to treatment are still largely assessed from imaging measurements of reductions in tumour size, which can take weeks to be manifest. This Review presents the new non-invasive techniques that can give early evidence of tumour response.
DNA vaccines: precision tools for activating effective immunity against cancer
Jason Rice, Christian H. Ottensmeier & Freda K. Stevenson
p108 | doi:10.1038/nrc2326
DNA vaccines against cancer allow a high degree of molecular precision, but until recently translation into the clinic has been difficult. Advances in delivery techniques are now allowing them to fulfil their potential.
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Anthony G. Letai
p121 | doi:10.1038/nrc2297
Cancer cells survive despite violating rules that ordinarily provoke apoptosis. Now that we understand more about how members of the BCL2 family of proteins regulate apoptosis, can we exploit our knowledge to more effectively target cancer cells?
Ral GTPases and cancer: linchpin support of the tumorigenic platform
Brian O. Bodemann & Michael A. White
p133 | doi:10.1038/nrc2296
The Ras-family G-proteins RALA and RALB seem to be key offenders in the subversion of core biological systems driving oncogenic transformation. This up-to-date Review focuses on current developments within this field.
Perspectives
Opinion
Is cell competition relevant to cancer?
Eduardo Moreno
p141 | doi:10.1038/nrc2252
This Perspective provides an intriguing look at cell competition, which was originally described in Drosophila melanogaster more than 30 years ago. How do cells compete with one another, and how might this process relate to cancer?
Science and society
Translation of new cancer treatments from pet dogs to humans
Melissa Paoloni & Chand Khanna
p147 | doi:10.1038/nrc2273
Naturally occurring cancers in pet dogs are similar to those in humans, and there is a growing interest in using studies in dogs to complement research in humans and mice. How can the study of pet dogs contribute to the development of new cancer therapeutics?